A Vancomycin Derivative with a Pyrophosphate-Binding Group: A Strategy to Combat Vancomycin-Resistant Bacteria

Area of Science:

• Microbiology
• Medicinal Chemistry
• Pharmacology

Background:

• Vancomycin resistance in Gram-positive bacteria is a growing global health threat.
• Existing treatments are becoming ineffective against emerging resistant strains.

Purpose of the Study:

• To develop a novel therapeutic agent to overcome vancomycin resistance.
• To enhance the efficacy of vancomycin against vancomycin-resistant bacteria (VRB).

Main Methods:

• Synthesis of a dipicolyl-vancomycin conjugate (Dipi-van).
• Evaluation of Dipi-van's in vitro activity against VRB.
• Assessment of Dipi-van's mechanism of action on bacterial cell-wall biosynthesis.
• Testing Dipi-van in a murine model of VRB kidney infection.

Main Results:

• Dipi-van demonstrated over 100-fold higher in vitro activity compared to vancomycin.
• The conjugate enhanced inhibition of bacterial cell-wall biosynthesis.
• No detectable resistance developed after serial passages.
• Significant reduction (5-log) in bacterial burden in vivo at 12 mg/kg.

Conclusions:

• Dipicolyl-vancomycin conjugate (Dipi-van) is a potent agent against vancomycin-resistant bacteria (VRB).
• The strategy of conjugating dipicolyl moiety enhances vancomycin's efficacy and overcomes resistance.
• Dipi-van shows significant therapeutic potential for treating VRB infections.